Investor Relations
Partner With the
Molecular Shield.
We are actively seeking acquisition partners and institutional investors to accelerate Phase 3 initiation. Access to our secure data room is available to qualified parties.
Request Data Room Access
Why Now?
Preparing for Phase 34 — Glioma program fully designed, regulatory pathway cleared, Type B FDA meeting in 2026.
De-Risked Platform — 180+ patients treated with strong safety signal. Three independent programs with consistent results.
Rare FDA Designations — Breakthrough Therapy, Fast Track, and Orphan Drug — a regulatory package rarely seen at this stage.
>$8B Market Opportunity — Global platform across the most prevalent chemoradiation-treated solid tumors with no competitive threat.
0+
Patients Treated. Zero Unexpected SAEs.
The safety profile is established. The efficacy is proven. The regulatory path is clear. The question is who leads this into Phase 3.